Inferra AI / Company / MRVI
Maravai Lifesciences Holdings, Inc.
MRVI · Health Care
Last earnings Aug 6, 2026
Key results
Quarterly revenuequarter
$47.4 million
Quarterly revenue of $47.4 million, Net loss of $(69.8) million (including a goodwill impairment of $30.4 million), and Adjusted EBITDA of $(10.4) million Appointed Bernd Brust as new Chief Executive Officer (CEO) and member of its board of directors, and Raj Asarpota as Chief Financial Officer (CFO)
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Nucleic Acid Production revenuequarter
$31.1 million
Nucleic Acid Production revenue was $31.1 million for the second quarter, representing a 43.1% decrease year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Revenuequarter
3.0%
Excluding revenue from high-volume CleanCap, revenue was up 3.0% year-over-year driven by growth in GMP products.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Biologics Safety Testing revenuequarter
$16.3 million
Biologics Safety Testing revenue was $16.3 million for the second quarter, up 9.9% year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Growthquarter
up 9.9%
Biologics Safety Testing revenue was $16.3 million for the second quarter, up 9.9% year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Nucleic Acid Production revenue was $59.8 million for the six months ended June 30, 2025, representing a 40.5% decrease year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Excluding revenue from high-volume CleanCap, revenue was down 11.0% year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Biologics Safety Testing revenue was $34.4 million for the six months ended June 30, 2025, up 4.3% year-over-year.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
AI analysis
Q2 2025 · reported Aug 11, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Quarterly revenue | $47.4 million | — | — |
| Nucleic Acid Production revenue | $31.1 million | — | — |
| Revenue | 3.0% | — | — |
| Biologics Safety Testing revenue | $16.3 million | — | — |
| Growth | up 9.9% | — | — |
Guidance · company-stated
Direction: Withdrawn
“Revenue Guidance for Full Year 2025 With the Chief Executive Officer and Chief Financial Officer transition, Maravai is withdrawing and suspending revenue guidance for 2025.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Since being appointed CEO, the leadership team and I have embarked on a thorough review of the business and have begun implementing actions expected to realize north of $50 million in annualized cost savings comprising of labor, facilities, capex and productivity initiatives to better align our cost structure with operational needs.
Maravai s potential failure to meet Maravai s debt service obligations.
Event summary
MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Withdrawn
Revenue — Withdrawn (“withdrawing”)
“Revenue Guidance for Full Year 2025 With the Chief Executive Officer and Chief Financial Officer transition, Maravai is withdrawing and suspending revenue guidance for 2025.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Since being appointed CEO, the leadership team and I have embarked on a thorough review of the business and have begun implementing actions expected to realize north of $50 million in annualized cost savings comprising of labor, facilities, capex and productivity initiatives to better align our cost structure with operational needs.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Maravai s potential failure to meet Maravai s debt service obligations.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Our potential failure to meet our debt service obligations.
SEC original ↗Maravai Lifesciences Holdings, Inc. — 10-Q Quarterly report10-QAug 7, 2026
As of June 30, 2026 and December 31, 2025, the fair value of the Company s long-term debt approximated its carrying value, excluding the effect of unamortized debt discount, as it is based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs).
SEC original ↗Maravai Lifesciences Holdings, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Long-Term Debt 2026 Credit Agreement On June 2, 2026, Maravai Intermediate Holdings, LLC, a wholly-owned subsidiary of Maravai Topco Holdings, LLC, as borrower, entered into a new credit agreement (the "2026 Credit Agreement") with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent.
SEC original ↗Maravai Lifesciences Holdings, Inc. — 10-Q Quarterly report10-QAug 7, 2026
The 2026 Credit Agreement provides for a $ 150.0 million initial term loan facility (the "2026 Term Loan") and a $ 30.0 million revolving credit facility (the "2026 Revolving Credit Facility"), each maturing on June 2, 2032.
SEC original ↗Maravai Lifesciences Holdings, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Strategy & priorities
htm EX-99.1 Document Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted EBITDA and Positive Free Cash Flow expected by second half 2026 SAN DIEGO, Calif.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Since being appointed CEO, the leadership team and I have embarked on a thorough review of the business and have begun implementing actions expected to realize north of $50 million in annualized cost savings comprising of labor, facilities, capex and productivity initiatives to better align our cost structure with operational needs.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Some of these actions impact valued colleagues, and we are approaching the process with care and respect, with a focus on minimizing disruption to our customers and putting Maravai on a path to return to profitability.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Instead, they are based only on management s current beliefs, expectations and assumptions regarding the future of Maravai s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Maravai s ability to efficiently manage its strategic acquisitions and organic growth opportunities.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Risks & headwinds
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of management s control.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Uncertainty regarding the extent and duration of Maravai s revenue associated with high-volume sales of CleanCap for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
and foreign trade policy, including the imposition of tariffs, trade restrictions and retaliatory actions, on demand for Maravai s products and services and Maravai s customers ability to commit funds to purchase such products and services.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Product liability lawsuits.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Risks and uncertainty related to the restatement of Maravai s previously issued financial statements.
SEC original ↗Maravai Lifesciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2025
Legal Proceedings 46 Item 1A.
SEC original ↗Maravai Lifesciences Holdings, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q2 2026
- 10-QMRVI
- 8-KMRVI
- Q1 2026
- 8-KMRVI
- 8-KMRVI
- 10-QMRVI
- 8-KMRVI
- Q4 2025
- 10-KMRVI
- 8-KMRVI
- Q3 2025
- 10-QMRVI
- 8-KMRVI
- 8-KMRVI
- Q2 2025
- 8-KMRVI
- 10-QMRVI
- 8-KMRVI
- Q1 2025
- 8-KMRVI
- EX-99MRVI
- 8-KMRVI
- 8-KMRVI
- 8-KMRVI
- 10-QMRVI
- Q4 2024
- 8-KMRVI
- 8-KMRVI
- 10-KMRVI
- 8-KMRVI
- EX-99MRVI
- 8-KMRVI
- EX-99MRVI
- Q3 2024
- 8-KMRVI
- 8-KMRVI
- 10-QMRVI
- 8-KMRVI
- Q2 2024
- 8-KMRVI
- 10-QMRVI
Earnings releases
9 documentsPresentations
0 documentsNo presentations for Maravai Lifesciences Holdings, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Maravai Lifesciences Holdings, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.